Abstract
The diagnosed incidence of small intestine neuroendocrine tumors (SI-NETs) is increasing, and the underlying genomic mechanisms have not yet been defined. Using exome- and genome-sequence analysis of SI-NETs, we identified recurrent somatic mutations and deletions in CDKN1B, the cyclin-dependent kinase inhibitor gene, which encodes p27. We observed frameshift mutations of CDKN1B in 14 of 180 SI-NETs, and we detected hemizygous deletions encompassing CDKN1B in 7 out of 50 SI-NETs, nominating p27 as a tumor suppressor and implicating cell cycle dysregulation in the etiology of SI-NETs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Vinik, A.I. et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas 39, 713–734 (2010).
Jiao, Y. et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 331, 1199–1203 (2011).
Kulke, M.H. et al. High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Genes Chromosom. Cancer 47, 591–603 (2008).
Cunningham, J.L. et al. Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. Genes Chromosom. Cancer 50, 82–94 (2011).
Banck, M.S. et al. The genomic landscape of small intestine neuroendocrine tumors. J. Clin. Invest. 123, 2502–2508 (2013).
Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013).
Lawrence, M.S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013).
Futreal, P.A. et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177–183 (2004).
Getz, G. et al. Comment on “The consensus coding sequences of human breast and colorectal cancers”. Science 317, 1500 (2007).
Hatta, Y., Takeuchi, S., Yokota, J. & Koeffler, H.P. Ovarian cancer has frequent loss of heterozygosity at chromosome 12p12.3–13.1 (region of TEL and Kip1 loci) and chromosome 12q23-ter: evidence for two new tumour-suppressor genes. Br. J. Cancer 75, 1256–1262 (1997).
Kibel, A.S., Freije, D., Isaacs, W.B. & Bova, G.S. Deletion mapping at 12p12–13 in metastatic prostate cancer. Genes Chromosom. Cancer 25, 270–276 (1999).
Takeuchi, S. et al. Frequent loss of heterozygosity in region of the KIP1 locus in non-small cell lung cancer: evidence for a new tumor suppressor gene on the short arm of chromosome 12. Cancer Res. 56, 738–740 (1996).
Pietenpol, J.A. et al. Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res. 55, 1206–1210 (1995).
Hetet, G. et al. Recurrent molecular deletion of the 12p13 region, centromeric to ETV6/TEL, in T-cell prolymphocytic leukemia. Hematol. J. 1, 42–47 (2000).
Le Toriellec, E. et al. Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia. Blood 111, 2321–2328 (2008).
Barbieri, C.E. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685–689 (2012).
Muraoka, R.S. et al. ErbB2/Neu-induced, cyclin D1–dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol. Cell Biol. 22, 2204–2219 (2002).
Gao, H. et al. A critical role for p27kip1 gene dosage in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. USA 101, 17204–17209 (2004).
Sancho, R. et al. F-box and WD repeat domain–containing 7 regulates intestinal cell lineage commitment and is a haploinsufficient tumor suppressor. Gastroenterology 139, 929–941 (2010).
Ying, H. et al. PTEN is a major tumor suppressor in pancreatic ductal adenocarcinoma and regulates an NF-κB–cytokine network. Cancer Discov. 1, 158–169 (2011).
Kumar, M.S. et al. Dicer1 functions as a haploinsufficient tumor suppressor. Genes Dev. 23, 2700–2704 (2009).
Zimmer, S.N. et al. Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis. Blood 118, 69–79 (2011).
Kiyokawa, H. et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 85, 721–732 (1996).
Nakayama, K. et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85, 707–720 (1996).
Fero, M.L. et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 85, 733–744 (1996).
Fero, M.L., Randel, E., Gurley, K.E., Roberts, J.M. & Kemp, C.J. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 396, 177–180 (1998).
The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330–337 (2012).
Solimini, N.L. et al. Recurrent hemizygous deletions in cancers may optimize proliferative potential. Science 337, 104–109 (2012).
Rudin, C.M. et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat. Genet. 44, 1111–1116 (2012).
Peifer, M. et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat. Genet. 44, 1104–1110 (2012).
Banerji, S. et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 486, 405–409 (2012).
Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107–1120 (2012).
Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883–892 (2012).
Habbe, N., Fendrich, V., Heverhagen, A., Ramaswamy, A. & Bartsch, D.K. Outcome of surgery for ileojejunal neuroendocrine tumors. Surg. Today 43, 1168–1174 (2013).
Polish, A., Vergo, M.T. & Agulnik, M. Management of neuroendocrine tumors of unknown origin. J. Natl. Compr. Canc. Netw. 9, 1397–1402 (2011).
Curtit, E. et al. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. Oncologist 18, 667–674 (2013).
Park, S. et al. Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in non-small cell lung cancer. J. Thorac. Oncol. 4, 809–815 (2009).
Polyak, K. et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78, 59–66 (1994).
Toyoshima, H. & Hunter, T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 78, 67–74 (1994).
The Cancer Genome Atlas. Comprehensive molecular portraits of human breast tumours. Nature 490, 61–70 (2012).
Stephens, P.J. et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 486, 400–404 (2012).
Pellegata, N.S. et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl. Acad. Sci. USA 103, 15558–15563 (2006).
Milne, T.A. et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc. Natl. Acad. Sci. USA 102, 749–754 (2005).
Karnik, S.K. et al. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc. Natl. Acad. Sci. USA 102, 14659–14664 (2005).
Fisher, S. et al. A scalable, fully automated process for construction of sequence-ready human exome targeted capture libraries. Genome Biol. 12, R1 (2011).
Li, H. & Durbin, R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 26, 589–595 (2010).
DePristo, M.A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet. 43, 491–498 (2011).
Pugh, T.J. et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature 488, 106–110 (2012).
Saunders, C.T. et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 28, 1811–1817 (2012).
Chiang, D.Y. et al. High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat. Methods 6, 99–103 (2009).
Mermel, C.H. et al. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12, R41 (2011).
Acknowledgements
This work was supported by grants from the Caring for Carcinoid Foundation (S.L.A. and M.M.), the Raymond and Beverly Sackler Foundation for the Arts and Sciences (C.T., A. Karpathakis, S.L.A. and M.M.) and Cancer Research UK (C.T. and A. Karpathakis).
Author information
Authors and Affiliations
Contributions
J.M.F., A. Kiezun, A.H.R., R.S., S.L.A., C.R.H., M.K. and M.M. conceived and designed the experiments. J.M.F., A. Kiezun, A.H.R., S.S., C.S.P., Z.R.Q., A. Karpathakis, S.O., C.T., R.S., S.L.A., C.R.H., G.G., M.K. and M.M. analyzed the data. C.S.P., Z.R.Q., M.S.B., R.K., A.A.K., A. Karpathakis, V.M., T.C., J.P., N.P., S.M.H., L.K.B., M.S.L., T.P., A.M., A.S., K.C., S.L.C., A.I.O., S.F., R.T.J., D.V., G.S., T.M., M.C., D.C.C., A.S.B., S.O., C.T., R.S., S.L.A., C.R.H., G.G., M.K., J.G., L.G. and N.L. contributed reagents, materials and tools. E.N., D.A., R.O., E.S. and C.S. provided project management support. J.M.F., A. Kiezun, A.H.R., S.L.A., M.K. and M.M. wrote the manuscript with contributions from all other authors.
Corresponding authors
Ethics declarations
Competing interests
M.M. is a paid consultant for and equity holder in Foundation Medicine, a genomics-based oncology diagnostics company.
Supplementary information
Supplementary Figures
Supplementary Figures 1–5 (PDF 5046 kb)
Supplementary Tables
Supplementary Tables 1–16 (XLSX 1785 kb)
Rights and permissions
About this article
Cite this article
Francis, J., Kiezun, A., Ramos, A. et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet 45, 1483–1486 (2013). https://doi.org/10.1038/ng.2821
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng.2821
This article is cited by
-
HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process
Scientific Reports (2024)
-
Exposure to nonanoic acid alters small intestinal neuroendocrine tumor phenotype
BMC Cancer (2023)
-
Neuroendocrine neoplasms of the lung and gastrointestinal system: convergent biology and a path to better therapies
Nature Reviews Clinical Oncology (2023)
-
Integrating Functional Imaging and Molecular Profiling for Optimal Treatment Selection in Neuroendocrine Neoplasms (NEN)
Current Oncology Reports (2023)
-
Multiple endocrine neoplasia type 4 (MEN4): a thorough update on the latest and least known men syndrome
Endocrine (2023)